INSERM UMR 1037-Cancer Research Center of Toulouse, Université de Toulouse III, Institut Claudius Regaud, Toulouse, France.
J Lipid Res. 2012 Apr;53(4):718-25. doi: 10.1194/jlr.M023689. Epub 2012 Jan 29.
We recently established that drugs used for the treatment and the prophylaxis of breast cancers, such as tamoxifen, were potent inhibitors of cholesterol-5,6-epoxide hydrolase (ChEH), which led to the accumulation of 5,6α-epoxy-cholesterol (5,6α-EC) and 5,6β-epoxy-cholesterol (5,6β-EC). This could be considered a paradox because epoxides are known as alkylating agents with putative carcinogenic properties. We report here that, as opposed to the carcinogen styrene-oxide, neither of the ECs reacted spontaneously with nucleophiles. Under catalytic conditions, 5,6β-EC remains unreactive whereas 5,6α-EC gives cholestan-3β,5α-diol-6β-substituted compounds. These data showed that 5,6-ECs are stable epoxides and unreactive toward nucleophiles in the absence of a catalyst, which contrasts with the well-known reactivity of aromatic and aliphatic epoxides. These data rule out 5,6-EC acting as spontaneous alkylating agents. In addition, these data support the existence of a stereoselective metabolism of 5,6α-EC.
我们最近证实,用于治疗和预防乳腺癌的药物,如他莫昔芬,是胆固醇-5,6-环氧化物水解酶(ChEH)的有效抑制剂,这导致 5,6α-环氧胆固醇(5,6α-EC)和 5,6β-环氧胆固醇(5,6β-EC)的积累。这可能被认为是一个矛盾,因为环氧化物是已知的具有潜在致癌特性的烷化剂。我们在这里报告,与致癌剂苯乙烯氧化物相反,这两种 EC 都不会自发与亲核试剂反应。在催化条件下,5,6β-EC 保持不反应,而 5,6α-EC 则生成胆甾烷-3β,5α-二醇-6β-取代化合物。这些数据表明,5,6-EC 在没有催化剂的情况下是稳定的环氧化物,不会与亲核试剂反应,这与众所周知的芳香族和脂肪族环氧化物的反应性形成对比。这些数据排除了 5,6-EC 作为自发烷化剂的作用。此外,这些数据支持 5,6α-EC 的立体选择性代谢的存在。